BridgeBio Pharma (BBIO) Change in Cash (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Change in Cash data on file, last reported at $309.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 320.55% year-over-year to $309.9 million; the trailing twelve-month figure through Mar 2026 stood at $339.3 million (up 420.0% YoY), and the FY2025 full-year result was -$111.1 million, down 138.51% from the prior year.
• Change in Cash grew to $309.9 million in Q1 2026, from -$73.0 million in the prior quarter.
• In the past five years, Change in Cash ranged from a high of $309.9 million in Q1 2026 to a low of -$141.6 million in Q3 2024.
• A 5-year average of $28.6 million and a median of $13.1 million in 2022 frame the typical range for Change in Cash.
• Across the five-year window, Change in Cash jumped 1418.35% in 2023 and slumped 269.76% in 2025, its largest moves.
• Tracing BBIO's Change in Cash over 5 years: stood at -$68.9 million in 2022, then plunged by 87.82% to -$129.4 million in 2023, then soared by 312.79% to $275.4 million in 2024, then tumbled by 126.49% to -$73.0 million in 2025, then surged by 524.75% to $309.9 million in 2026.
• Business Quant data shows BBIO's Change in Cash at $309.9 million in Q1 2026, -$73.0 million in Q4 2025, and -$106.0 million in Q3 2025.